Ropes & Gray Represents Summa Equity in its Sale of Protein Biomarker Platform Olink to Thermo Fisher Scientific

Ropes & Gray advised Summa Equity AB, Olink Holding AB’s largest shareholder, in a sale to Thermo Fisher Scientific Inc. Olink products and services provide pharmaceutical companies and clinical and academic institutions with proteomics research across disease areas. Thermo Fisher will commence a tender offer to acquire all of the outstanding Olink common shares and all of the American Depositary Shares. The transaction, which values Olink at approximately $3.1 billion and includes net cash of approximately $143 million, was announced in a press release on October 17.

Summa Equity is a purpose-driven investment firm, investing across the themes of Resource Efficiency, Changing Demographics, and Tech-Enabled Transformation. Summa’s purpose is to co-create win-win for investors, portfolio companies, and society through aligning its vision and investing in line with the United Nation’s Sustainable Development Goals.

The Ropes & Gray team that represented Summa Equity was led by mergers & acquisition partner Suni Sreepada, executive compensation & employee benefits partners Renata Ferrari and Kyle Higley, tax partner Ben Rogers, capital markets & governance partner Chris Capuzzi and counsel Marc Rotter, asset management partner Yoni Levy and mergers & acquisitions associate Dan Sotsky.